Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats

Tomáš Páleníček, Michaela Fujáková, Martin Brunovský, Jiří Horáček, Ingmar Gorman, Marie Balíková, Lukáš Rambousek, Kamila Syslová, Petr Kačer, Petr Zach, Věra Bubeníková-Valešová, Filip Tylš, Anna Kubešová, Jana Puskarčíková, Cyril Höschl

. 2013 ; 225 (1) : 75-93.

Jazyk angličtina Země Německo

Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc13024370

Grantová podpora
NS10374 MZ0 CEP - Centrální evidence projektů
NS10375 MZ0 CEP - Centrální evidence projektů
NT13897 MZ0 CEP - Centrální evidence projektů

RATIONALE AND OBJECTIVES: Behavioral, neurochemical and pharmaco-EEG profiles of a new synthetic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats were examined. MATERIALS AND METHODS: Locomotor effects, prepulse inhibition (PPI) of acoustic startle reaction (ASR), dopamine and its metabolite levels in nucleus accumbens (NAc), EEG power spectra and coherence in freely moving rats were analysed. Amphetamine was used as a reference compound. RESULTS: 2C-B had a biphasic effect on locomotion with initial inhibitory followed by excitatory effect; amphetamine induced only hyperlocomotion. Both drugs induced deficits in the PPI; however they had opposite effects on ASR. 2C-B increased dopamine but decreased 3,4-dihydroxyphenylacetic acid (DOPAC) in the NAc. Low doses of 2C-B induced a decrease in EEG power spectra and coherence. On the contrary, high dose of 2C-B 50 mg/kg had a temporally biphasic effect with an initial decrease followed by an increase in EEG power; decrease as well as increase in EEG coherence was observed. Amphetamine mainly induced an increase in EEG power and coherence in theta and alpha bands. Increases in the theta and alpha power and coherence in 2C-B and amphetamine were temporally linked to an increase in locomotor activity and DA levels in NAc. CONCLUSIONS: 2C-B is a centrally active compound similar to other hallucinogens, entactogens and stimulants. Increased dopamine and decreased DOPAC in the NAc may reflect its psychotomimetic and addictive potential and monoaminoxidase inhibition. Alterations in brain functional connectivity reflected the behavioral and neurochemical changes produced by the drug; a correlation between EEG changes and locomotor behavior was observed.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13024370
003      
CZ-PrNML
005      
20181010101905.0
007      
ta
008      
130703s2013 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00213-012-2797-7 $2 doi
035    __
$a (PubMed)22842791
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Páleníček, Tomáš, $u Prague Psychiatric Center, Prague, Czech Republic. palenicek@pcp.lf3.cuni.cz $d 1976- $7 mzk2004257555
245    10
$a Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats / $c Tomáš Páleníček, Michaela Fujáková, Martin Brunovský, Jiří Horáček, Ingmar Gorman, Marie Balíková, Lukáš Rambousek, Kamila Syslová, Petr Kačer, Petr Zach, Věra Bubeníková-Valešová, Filip Tylš, Anna Kubešová, Jana Puskarčíková, Cyril Höschl
520    9_
$a RATIONALE AND OBJECTIVES: Behavioral, neurochemical and pharmaco-EEG profiles of a new synthetic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats were examined. MATERIALS AND METHODS: Locomotor effects, prepulse inhibition (PPI) of acoustic startle reaction (ASR), dopamine and its metabolite levels in nucleus accumbens (NAc), EEG power spectra and coherence in freely moving rats were analysed. Amphetamine was used as a reference compound. RESULTS: 2C-B had a biphasic effect on locomotion with initial inhibitory followed by excitatory effect; amphetamine induced only hyperlocomotion. Both drugs induced deficits in the PPI; however they had opposite effects on ASR. 2C-B increased dopamine but decreased 3,4-dihydroxyphenylacetic acid (DOPAC) in the NAc. Low doses of 2C-B induced a decrease in EEG power spectra and coherence. On the contrary, high dose of 2C-B 50 mg/kg had a temporally biphasic effect with an initial decrease followed by an increase in EEG power; decrease as well as increase in EEG coherence was observed. Amphetamine mainly induced an increase in EEG power and coherence in theta and alpha bands. Increases in the theta and alpha power and coherence in 2C-B and amphetamine were temporally linked to an increase in locomotor activity and DA levels in NAc. CONCLUSIONS: 2C-B is a centrally active compound similar to other hallucinogens, entactogens and stimulants. Increased dopamine and decreased DOPAC in the NAc may reflect its psychotomimetic and addictive potential and monoaminoxidase inhibition. Alterations in brain functional connectivity reflected the behavioral and neurochemical changes produced by the drug; a correlation between EEG changes and locomotor behavior was observed.
650    _2
$a kyselina 3,4-dihydroxyfenyloctová $x metabolismus $7 D015102
650    _2
$a amfetamin $x farmakologie $7 D000661
650    _2
$a zvířata $7 D000818
650    _2
$a chování zvířat $x účinky léků $7 D001522
650    _2
$a dimethoxyfenylethylamin $x aplikace a dávkování $x analogy a deriváty $x farmakologie $7 D004118
650    _2
$a dopamin $x metabolismus $7 D004298
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a elektroencefalografie $7 D004569
650    _2
$a halucinogeny $x aplikace a dávkování $x farmakologie $7 D006213
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a pohybová aktivita $x účinky léků $7 D009043
650    _2
$a nucleus accumbens $x účinky léků $x metabolismus $7 D009714
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a úleková reakce $x účinky léků $7 D013216
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Fujáková, Michaela $u Prague Psychiatric Center, Prague, Czech Republic; 3rd Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $7 _AN027808
700    1_
$a Brunovský, Martin, $u Prague Psychiatric Center, Prague, Czech Republic $d 1975- $7 xx0070660
700    1_
$a Horáček, Jiří, $u Prague Psychiatric Center, Prague, Czech Republic $d 1966- $7 jo2002152353
700    1_
$a Gorman, Ingmar $u Prague Psychiatric Center, Prague, Czech Republic $7 _AN045561
700    1_
$a Balíková, Marie, $u Institute of Forensic Medicine and Toxicology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $d 1945- $7 jn99240000049
700    1_
$a Rambousek, Lukáš, $u Institute of Chemical Technology, Prague, Czech Republic; Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic $d 1986- $7 xx0107401
700    1_
$a Syslová, Kamila $u Institute of Chemical Technology, Prague, Czech Republic $7 xx0145898
700    1_
$a Kačer, Petr, $u Institute of Chemical Technology, Prague, Czech Republic $d 1969- $7 xx0081992
700    1_
$a Zach, Petr $u 3rd Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $7 xx0071037
700    1_
$a Valešová, Věra, $u Prague Psychiatric Center, Prague, Czech Republic $d 1977- $7 nlk20050173200
700    1_
$a Tylš, Filip, $u Prague Psychiatric Center, Prague, Czech Republic; 3rd Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $d 1985- $7 xx0218168
700    1_
$a Kubešová, Anna $u Prague Psychiatric Center, Prague, Czech Republic; 3rd Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $7 _AN064719
700    1_
$a Puskarčíková, Jana $u Prague Psychiatric Center, Prague, Czech Republic; 3rd Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $7 _AN059942
700    1_
$a Höschl, Cyril, $u Prague Psychiatric Center, Prague, Czech Republic $d 1949- $7 jn20000401149
773    0_
$w MED00003990 $t Psychopharmacology $x 1432-2072 $g Roč. 225, č. 1 (2013), s. 75-93
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22842791 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20130703 $b ABA008
991    __
$a 20181010102354 $b ABA008
999    __
$a ok $b bmc $g 988050 $s 822750
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 225 $c 1 $d 75-93 $i 1432-2072 $m Psychopharmacology $n Psychopharmacology $x MED00003990
GRA    __
$a NS10374 $p MZ0
GRA    __
$a NS10375 $p MZ0
GRA    __
$a NT13897 $p MZ0
LZP    __
$a Pubmed-20130703
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace